Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$230.25 -1.8%	$196.96	$96.09 ▼ $238.56	$12.07B	0.59	725,919 shs	499,087 shs
DYN Dyne Therapeutics	$18.63 -3.6%	$18.31	$8.06 ▼ $25.00	$3.20B	1.09	1.34 million shs	1.44 million shs
ELAN Elanco Animal Health	$23.70 -0.6%	$22.93	$13.09 ▼ $27.72	$11.91B	1.69	7.67 million shs	5.32 million shs
RGC Regencell Bioscience	$24.17 +1.1%	$27.67	$9.39 ▼ $83.60	$11.82B	1.88	100,792 shs	73,268 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-1.80%	-2.42%	+11.49%	+40.35%	+119.45%
DYN Dyne Therapeutics	-3.62%	+7.25%	+7.13%	+27.60%	+57.61%
ELAN Elanco Animal Health	-0.65%	+8.89%	+5.15%	-4.61%	+76.11%
RGC Regencell Bioscience	+1.13%	-6.32%	-17.00%	+0.75%	+2,416,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$230.25 -1.8%	$196.96	$96.09 ▼ $238.56	$12.07B	0.59	725,919 shs	499,087 shs
DYN Dyne Therapeutics	$18.63 -3.6%	$18.31	$8.06 ▼ $25.00	$3.20B	1.09	1.34 million shs	1.44 million shs
ELAN Elanco Animal Health	$23.70 -0.6%	$22.93	$13.09 ▼ $27.72	$11.91B	1.69	7.67 million shs	5.32 million shs
RGC Regencell Bioscience	$24.17 +1.1%	$27.67	$9.39 ▼ $83.60	$11.82B	1.88	100,792 shs	73,268 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-1.80%	-2.42%	+11.49%	+40.35%	+119.45%
DYN Dyne Therapeutics	-3.62%	+7.25%	+7.13%	+27.60%	+57.61%
ELAN Elanco Animal Health	-0.65%	+8.89%	+5.15%	-4.61%	+76.11%
RGC Regencell Bioscience	+1.13%	-6.32%	-17.00%	+0.75%	+2,416,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	2.90	Moderate Buy	$251.26	9.13% Upside
DYN Dyne Therapeutics	2.94	Moderate Buy	$35.00	87.87% Upside
ELAN Elanco Animal Health	2.77	Moderate Buy	$28.20	18.97% Upside
RGC Regencell Bioscience	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest DYN, AXSM, ELAN, and RGC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2026	DYN Dyne Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00
5/13/2026	DYN Dyne Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Perform	$23.00 ➝ $24.00
5/11/2026	ELAN Elanco Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
5/7/2026	ELAN Elanco Animal Health	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $31.00
5/7/2026	ELAN Elanco Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$28.00 ➝ $30.00
5/5/2026	AXSM Axsome Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$280.00
5/5/2026	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$225.00 ➝ $255.00
5/5/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$242.00 ➝ $302.00
5/5/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$270.00 ➝ $290.00
5/5/2026	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$217.00 ➝ $242.00
5/5/2026	AXSM Axsome Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$225.00 ➝ $255.00

(Data available from 6/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$708.24M	16.73	N/A	N/A	$1.75 per share	131.57
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
ELAN Elanco Animal Health	$4.89B	2.42	$2.31 per share	10.28	$13.18 per share	1.80
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$183.17M	-$3.73	N/A	49.52	N/A	-26.59%	-267.16%	-28.53%	8/3/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.22	N/A	N/A	N/A	N/A	-58.28%	-46.77%	7/27/2026 (Estimated)
ELAN Elanco Animal Health	-$232M	-$0.50	N/A	19.59	2.57	-4.95%	7.42%	3.66%	8/6/2026 (Estimated)
RGC Regencell Bioscience	-$3.58M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest DYN, AXSM, ELAN, and RGC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/11/2026	Q1 2026	DYN Dyne Therapeutics	-$0.7723	-$0.73	+$0.0423	-$0.73	N/A	N/A
5/8/2026	Q1 2026	RGC Regencell Bioscience	N/A	-$0.0050	N/A	-$0.0050	N/A	N/A
5/6/2026	Q1 2026	ELAN Elanco Animal Health	$0.34	$0.40	+$0.06	$0.11	$1.28 billion	$1.37 billion
5/4/2026	Q1 2026	AXSM Axsome Therapeutics	-$0.85	-$1.26	-$0.41	-$1.26	$191.10 million	$191.20 million
3/2/2026	Q4 2025	DYN Dyne Therapeutics	-$0.74	-$0.76	-$0.02	-$0.76	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	2.27	1.39	1.32
DYN Dyne Therapeutics	0.17	19.92	19.92
ELAN Elanco Animal Health	0.60	2.16	1.12
RGC Regencell Bioscience	N/A	1.41	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
DYN Dyne Therapeutics	96.68%
ELAN Elanco Animal Health	97.48%
RGC Regencell Bioscience	0.13%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	20.60%
DYN Dyne Therapeutics	9.46%
ELAN Elanco Animal Health	1.14%
RGC Regencell Bioscience	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	51.46 million	40.86 million	Optionable
DYN Dyne Therapeutics	100	165.31 million	149.68 million	Optionable
ELAN Elanco Animal Health	9,400	499.45 million	493.76 million	Optionable
RGC Regencell Bioscience	10	494.49 million	N/A	N/A

DYN, AXSM, ELAN, and RGC Headlines

Recent News About These Companies

RGC DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGC

June 1 at 10:55 PM | newsfilecorp.comN

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 23, 2026 in ...

June 1 at 5:56 PM | caledonianrecord.comC

Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

June 1 at 4:15 PM | prnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 23, 2026 in Regencell Bioscience Holdings Limited Lawsuit - RGC

June 1 at 2:52 PM | globenewswire.com

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regencell (RGC) Investors of Securities Class Action Deadline on June 23, 2026

June 1 at 12:22 PM | newsfilecorp.comN

RGC DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGC

May 31 at 9:35 PM | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

May 31 at 12:00 PM | newsfilecorp.comN

RGC CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026

May 30 at 8:14 AM | newsfilecorp.comN

Lost Money on Regencell Bioscience Holdings Limited (RGC)? Join Class Action Suit Seeking ...

May 29, 2026 | caledonianrecord.comC

RGC DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGC

May 29, 2026 | newsfilecorp.comN

Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Regencell Bioscience Holdings Limited and Encourages Investors to Contact the Firm Before June 23rd

May 29, 2026 | globenewswire.com

Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

May 29, 2026 | prnewswire.com

Lost Money on Regencell Bioscience Holdings Limited (RGC)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

May 29, 2026 | globenewswire.com

Deadline Alert: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged ...

May 28, 2026 | enidnews.comE

RGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026

May 28, 2026 | newsfilecorp.comN

Regencell Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

May 28, 2026 | prnewswire.com

Deadline Alert: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

May 28, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

May 28, 2026 | newsfilecorp.comN

Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC

May 28, 2026 | prnewswire.com

SueWallSt Reminds Regencell Bioscience Holdings Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 23, 2026 - RGC

May 28, 2026 | prnewswire.com

Regencell Bioscience (NASDAQ:RGC) Trading Down 9% - What's Next?

May 8, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DYN, AXSM, ELAN, and RGC Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$230.25 -4.23 (-1.80%)

Closing price 06/1/2026 04:00 PM Eastern

Extended Trading

$232.65 +2.40 (+1.04%)

As of 05:33 AM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Dyne Therapeutics NASDAQ:DYN

$18.63 -0.70 (-3.62%)

Closing price 06/1/2026 04:00 PM Eastern

Extended Trading

$18.71 +0.08 (+0.45%)

As of 04:29 AM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Elanco Animal Health NYSE:ELAN

$23.70 -0.15 (-0.61%)

Closing price 06/1/2026 03:59 PM Eastern

Extended Trading

$23.53 -0.17 (-0.73%)

As of 05:56 AM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Regencell Bioscience NASDAQ:RGC

$24.17 +0.27 (+1.13%)

Closing price 06/1/2026 04:00 PM Eastern

Extended Trading

$24.05 -0.12 (-0.50%)

As of 04:15 AM Eastern

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DYN, AXSM, ELAN, and RGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DYN, AXSM, ELAN, and RGC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DYN, AXSM, ELAN, and RGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DYN, AXSM, ELAN, and RGC Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Dyne Therapeutics NASDAQ:DYN

Elanco Animal Health NYSE:ELAN

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DYN, AXSM, ELAN, and RGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DYN, AXSM, ELAN, and RGC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DYN, AXSM, ELAN, and RGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DYN, AXSM, ELAN, and RGC Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Dyne Therapeutics NASDAQ:DYN

Elanco Animal Health NYSE:ELAN

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools